D-Luciferin

Catalog No.S7763 Batch:S776303

Print

Technical Data

Formula

C11H8N2O3S2
Molecular Weight 280.32 CAS No. 2591-17-5
Solubility (25°C)* In vitro DMSO 56 mg/mL (199.77 mM)
Ethanol 1 mg/mL (3.56 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description D-Luciferin is a popular bioluminescent substrate of luciferase in the presence of ATP, used in luciferase-based bioluminescence imaging and cell-based high-throughput screening applications. In an immunocompetent mouse model of ovarian cancer, the use of D-luciferin substrate and firefly luciferase preserves tumour-host immune interactions since bioluminescent imaging is a more sensitive indication of tumour growth than weight gain.
In vitro

1.Example protocol for in vitro bioluminescent image assays
a) Prepare a 100 mM (100-200X) Luciferin stock solution in sterile water. Mix well. Use immediately, or make single use aliquots, and store at -20℃, avoid freeze-thaw cycles, avoid exposure to the light.
b) Prepare a 0.5-1 mM working solution of D-Luciferin in pre-warmed tissue culture medium.
c) Aspirate media from cultured cells.
d) Add Luciferin working solution to cells, and incubate the cells for 5-10 minutes at 37℃ just prior to imaging.
2.Example protocol for in vivo bioluminescent image assays
a) Prepare a 15 mg/mL Luciferin stock solution in DPBS, without Mg2+ and Ca2+. Mix well.
b) Filter sterilizes the solution through a 0.2 μm filter. Use immediately, or make single use aliquots, and store at -20℃, avoid freeze-thaw cycles, avoid exposure to the light.
c) Inject the luciferin intra-peritoneally (i.p.) 10-15 minutes before imaging at 150 mg/kg (or 10 μL/g of luciferin stock solution) of the animal body weight.
Note: A kinetic study of luciferin should be performed for each animal model to determine peak signal time.
3.Example protocol for luciferin reporter assays
a) Prepare a 100 mM Luciferin stock solution in sterile water. Use immediately, or make single use aliquots, and store at -20℃, avoid freeze-thaw cycles, avoid exposure to the light.
b) Prepare a 1 mM working solution of D-Luciferin with 3 mM ATP, 1 mM DTT and 15 mM MgSO4 in 25 mM tricine buffer pH 7.8.
c) Pipette 5-10 μLof cell lysate into a microplate. Use lysis reagent or buffer without lysate as a blank.
d) Prime luminometer with luciferin working solution.
e) Inject 200 μL of luciferin working solution with no delay and a 10 second integration time.
In vivo

In an immunocompetent mouse model of ovarian cancer, use of D-luciferin substrate and firefly luciferase preserves tumor-host immune interactions, since bioluminescent imaging is a more sensitive indication of tumor growth than weight gain. [2]

Protocol (from reference)

Animal Study:

[3]
  • Animal Models

    Female BALB/c nu/nu mice

  • Dosages

    75 mg/kg

  • Administration

    s.c.

Selleck's D-Luciferin has been cited by 8 publications

Carbenoxolone disodium suppresses the migration of gastric cancer by targeting HDAC6 [ Future Med Chem, 2023, 15(4):333-344] PubMed: 36946221
Crosstalk between pro-survival sphingolipid metabolism and complement signaling induces inflammasome-mediated tumor metastasis [ Cell Rep, 2022, 41(10):111742] PubMed: 36476873
A magneto-controlled biocatalytic cascade with a fluorescent output [ Org Biomol Chem, 2022, 20(9):1869-1873] PubMed: 35156979
Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc- for Glutathione Synthesis in Lung Cancer [ Cancer Res, 2021, 81(3):552-566] PubMed: 33229341
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy [ Breast Cancer Res, 2021, 23(1):11] PubMed: 33485378
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma [ Biochem Biophys Res Commun, 2021, 550:77-83] PubMed: 33689883
Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc- for Glutathione Synthesis in Lung Cancer [ Cancer Res, 2020, canres.0617.2020] PubMed: 33229341
Tumor treating fields increases membrane permeability in glioblastoma cells [ Cell Death Discov, 2018, 4:113] PubMed: 30534421

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.